Understanding and Treating Glioblastoma

For newly diagnosed patients, the standard has remained largely unchanged for the past decade and concept-driven approaches like antiangiogenic therapies or use of molecularly targeted drugs in all-comers populations have failed. Tumor-treating fields appear as a new option. Most current immunotherapy or molecularly targeted, precision medicine trials are also focusing on this newly diagnosed patient population. At progression, no standard exists and most treatments offer little beyond supportive care. Past trials lacked target precision and all-corners approaches have produced false negative results. Molecular precision approaches at progression need workup of recent rather than archival tissue.